{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T05:22:47Z","timestamp":1769059367565,"version":"3.49.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>The role of MZ phenotype of \u03b1 1 antitrypsin (\u03b11AT) deficiency as a potential cofactor in advanced liver disease arising from other primary causes is not widely understood. In the general population, MZ phenotype accounts for 2%\u20134% in Europe and 2%\u20137.1% in North America. The aim of this study was to determine the prevalence of the MZ phenotype among various causes of cirrhosis in the United States in the modern era and its impact on pulmonary function before and after liver transplantation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>This retrospective study included adult patients with cirrhosis who underwent liver transplantation at Mayo Clinic. Participants\u2019 data including pathogenesis of cirrhosis, model for end-stage liver disease-Na score, \u03b11AT phenotype, liver decompensation events, and pulmonary outcomes was determined by retrospective review of the liver transplantation database.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>One hundred thirty of 1341 adult patients with cirrhosis (9.7%) were \u03b11AT MZ carriers. When comparing the distribution of protease inhibitor (PI) MZ among different pathogenesis, the prevalence of MZ was significantly increased in nonalcoholic steatohepatitis (NASH), alcoholic liver disease (ALD), and cryptogenic cirrhosis compared with other causes. Thirty-seven of 171 with NASH (22%), 37 of 187 with ALD (20%), and 9 of 39 with cryptogenic cirrhosis (23.1%) were identified as PI MZ, while in other subgroups; we detected 18 of 320 with viral hepatitis, and 11 of 339 with primary biliary cholangitis\/primary sclerosing cholangitis. Also, MZ patients were more likely to develop preoperative chronic obstructive lung disease, and postoperative pulmonary hypertension and pulmonary embolism than MM patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>The rates of preoperative and postoperative pulmonary complications were found to be higher in PI MZ patients than in PI MM patients. The MZ phenotype was significantly enriched in NASH, ALD, and cryptogenic cirrhosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000003390","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T12:53:54Z","timestamp":1596027234000},"page":"1576-1584","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Association of \u03b1 1 Antitrypsin Phenotype and Development of Advanced Liver Disease and Pulmonary Complications Before and After Liver Transplantation"],"prefix":"10.1097","volume":"105","author":[{"given":"Anan","family":"Abu Rmilah","sequence":"first","affiliation":[{"name":"William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic College of Medicine, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Fencl","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kymberly","family":"Watt","sequence":"additional","affiliation":[{"name":"William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic College of Medicine, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Krowka","sequence":"additional","affiliation":[{"name":"William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic College of Medicine, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Wiesner","sequence":"additional","affiliation":[{"name":"William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic College of Medicine, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Murray","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Nyberg","sequence":"additional","affiliation":[{"name":"William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic College of Medicine, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Leise","sequence":"additional","affiliation":[{"name":"William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic College of Medicine, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/NJH.0b013e318295ea27","article-title":"The transition to end-of-life care in end-stage liver disease.","volume":"15","author":"Cox-North","year":"2013","journal-title":"J Hospice Palliative Nurs"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0140-6736(16)31470-2","article-title":"Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","article-title":"Liver cirrhosis.","volume":"371","author":"Schuppan","year":"2008","journal-title":"Lancet"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1053\/j.gastro.2016.01.037","article-title":"Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease.","volume":"150","author":"Anstee","year":"2016","journal-title":"Gastroenterology"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.mcna.2009.03.002","article-title":"Diagnosis and epidemiology of cirrhosis.","volume":"93","author":"Lefton","year":"2009","journal-title":"Med Clin North Am"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/hep.26051","article-title":"Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness.","volume":"57","author":"Innes","year":"2013","journal-title":"Hepatology"},{"key":"R7-20250604","article-title":"\u03b11-Antitrypsin deficiency.","volume":"2","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1056\/NEJMcp0900449","article-title":"Clinical practice. alpha1-antitrypsin deficiency.","volume":"360","author":"Silverman","year":"2009","journal-title":"N Engl J Med"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/thx.2003.012856","article-title":"Familial aggregation of FEF(25-75) and FEF(25-75)\/FVC in families with severe, early onset COPD.","volume":"59","author":"DeMeo","year":"2004","journal-title":"Thorax"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cgh.2011.12.028","article-title":"Diagnosis and management of patients with \u03b11-antitrypsin (A1AT) deficiency.","volume":"10","author":"Nelson","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/gutjnl-2018-316228","article-title":"Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis.","volume":"68","author":"Strnad","year":"2019","journal-title":"Gut"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"e8320","DOI":"10.1097\/MD.0000000000008320","article-title":"The prevalence of PI*S and PI*Z SERPINA1 alleles in healthy individuals and COPD patients in Saudi Arabia: a case-control study.","volume":"96","author":"Al-Jameil","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.21628","article-title":"Molecular pathogenesis of alpha-1-antitrypsin deficiency-associated liver disease: a meeting review.","volume":"45","author":"Perlmutter","year":"2007","journal-title":"Hepatology"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-0029-1192060","article-title":"Evolving surgical approaches in liver transplantation.","volume":"29","author":"Petrowsky","year":"2009","journal-title":"Semin Liver Dis"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jamcollsurg.2012.12.050","article-title":"Liver transplantation for lethal genetic syndromes: a novel model of personalized genomic medicine.","volume":"216","author":"Petrowsky","year":"2013","journal-title":"J Am Coll Surg"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"e7434","DOI":"10.5812\/hepatmon.7434","article-title":"Alpha-1 antitrypsin deficiency PI*Z and PI*S gene frequency distribution using on maps of the world by an inverse distance weighting (IDW) multivariate interpolation method.","volume":"12","author":"Blanco","year":"2012","journal-title":"Hepat Mon"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1378\/chest.12-0564","article-title":"\u03b11-Antitrypsin phenotypes and associated serum protein concentrations in a large clinical population.","volume":"143","author":"Bornhorst","year":"2013","journal-title":"Chest"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/1753465810365158","article-title":"Ethnic differences in alpha-1 antitrypsin deficiency in the United States of America.","volume":"4","author":"de Serres","year":"2010","journal-title":"Ther Adv Respir Dis"},{"key":"R19-20250604","first-page":"160","article-title":"Heterozygous alpha-I antitrypsin deficiency as a co-factor in the development of chronic liver disease: a review.","volume":"65","author":"Kok","year":"2007","journal-title":"Neth J Med"},{"key":"R20-20250604","first-page":"602","article-title":"Heterozygous alpha 1-antitrypsin phenotypes in patients with end stage liver disease.","volume":"92","author":"Eigenbrodt","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0168-8278(00)80119-1","article-title":"Chronic liver disease in heterozygous alpha1-antitrypsin deficiency PiZ.","volume":"33","author":"Fischer","year":"2000","journal-title":"J Hepatol"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00428-014-1633-3","article-title":"\u0391.","volume":"465","author":"Goltz","year":"2014","journal-title":"Virchows Arch"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.510280421","article-title":"Increased risk of chronic liver failure in adults with heterozygous alpha1-antitrypsin deficiency.","volume":"28","author":"Graziadei","year":"1998","journal-title":"Hepatology"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1097\/01.mpg.0000226387.56612.1e","article-title":"Does the heterozygous state of alpha-1 antitrypsin deficiency have a role in chronic liver diseases? Interim results of a large case-control study.","volume":"43","author":"Regev","year":"2006","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/lt.25057","article-title":"Heterozygosity for the alpha-1-antitrypsin Z allele in cirrhosis is associated with more advanced disease.","volume":"24","author":"Schaefer","year":"2018","journal-title":"Liver Transpl"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1183\/09031936.00015608","article-title":"Pulmonary hypertension in COPD.","volume":"32","author":"Chaouat","year":"2008","journal-title":"Eur Respir J"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1503\/cmaj.111749","article-title":"Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease.","volume":"184","author":"Brode","year":"2012","journal-title":"CMAJ"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"170068","DOI":"10.1183\/16000617.0068-2017","article-title":"COPD in individuals with the PiMZ alpha-1 antitrypsin genotype.","volume":"26","author":"Al Ashry","year":"2017","journal-title":"Eur Respir Rev"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"e42728","DOI":"10.1371\/journal.pone.0042728","article-title":"SERPINA1 PiZ and PiS heterozygotes and lung function decline in the SAPALDIA cohort.","volume":"7","author":"Thun","year":"2012","journal-title":"PLoS One"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1378\/chest.10-0746","article-title":"\u03b1.","volume":"138","author":"S\u00f8rheim","year":"2010","journal-title":"Chest"},{"key":"R31-20250604","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1165\/ajrcmb.20.2.3177","article-title":"Z and S mutations of the alpha1-antitrypsin gene and the risk of chronic obstructive pulmonary disease.","volume":"20","author":"Sandford","year":"1999","journal-title":"Am J Respir Cell Mol Biol"},{"key":"R32-20250604","article-title":"Unique case of alpha 1-antitrypsin deficiency causing decreased protein C and S activity leading to DVT and pulmonary embolism.","volume":"2","author":"Manoj","year":"2018","journal-title":"J Pulmonol Clin Res"},{"key":"R33-20250604","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2147\/COPD.S80173","article-title":"Identification of a novel SERPINA-1 mutation causing alpha-1 antitrypsin deficiency in a patient with severe bronchiectasis and pulmonary embolism.","volume":"10","author":"Milger","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"R34-20250604","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/bjd.13611","article-title":"Alpha-1-antitrypsin deficiency panniculitis presenting with severe anasarca, pulmonary embolus and hypogammaglobulinaemia.","volume":"173","author":"Elsensohn","year":"2015","journal-title":"Br J Dermatol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T19:09:24Z","timestamp":1749064164000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003390","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,6]]}}}